Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 4, 2014, Pages 509-527

  Gajate, Consuelo ^a   Mollinedo, Faustino ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Apoptosis; CASMER; Death receptor; Edelfosine; Endoplasmic reticulum stress; Ether phospholipid; Lipid rafts; Mitochondria

Indexed keywords

DEATH RECEPTOR; EDELFOSINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; RAF PROTEIN;

ACIDIFICATION; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; EUKARYOTIC CELL; HUMAN; IMMUNOPRECIPITATION; LIPID RAFT; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOLID TUMOR; SOLUBILIZATION; YEAST;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMANS; MEMBRANE MICRODOMAINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEOPLASMS; PHOSPHOLIPID ETHERS;

EID: 84908121687     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140309222259     Document Type: Article

References (216)

1. Munder, P.G.; Westphal, O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol., 1990, 49, 206-235.
2. Gajate, C.; Mollinedo, F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug Metab., 2002, 3, 491-525.
3. Andreesen, R.; Modolell, M.; Munder, P.G. Selective sensitivity of chronic myelogenous leukemia cell populations to alkyl-lysophospholipids. Blood, 1979, 54, 519-523.
4. Andreesen, R.; Modolell, M.; Weltzien, H.U.; Eibl, H.; Common HH.; Lohr GW.; Munder PG. Selective destruction of human leukemic cells by alkyl- lysophospholipids. Cancer Res., 1978, 38, 3894-3899.
5. Eibl, H.; Unger, C. Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev., 1990, 17, 233-242.
6. Leonard, R.; Hardy, J.; Van Tienhoven, G.; Houston, S.; Simmonds, P.; David, M.; Mansi, J. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol., 2001, 19, 4150-4159.
7. Mollinedo, F. Antitumor ether lipids: proapoptotic agents with multiple therapeutic indications. Exp. Opin. Ther. Patents, 2007, 17, 385-405.
8. Hilgard, P.; Klenner, T.; Stekar, J.; Nossner, G.; Kutscher, B.; Engel, J. D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur. J. Cancer, 1997, 33, 442-446.
9. Diomede, L.; Colotta, F.; Piovani, B.; Re, F.; Modest, E.J.; Salmona, M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer, 1993, 53, 124-130.
10. Mollinedo, F.; Martinez-Dalmau, R.; Modolell, M. Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem. Biophys. Res. Commun., 1993, 192, 603-609.
11. Mollinedo, F.; Fernandez-Luna, J.L.; Gajate, C.; Martin-Martin, B.; Benito, A.; Martinez-Dalmau, R.; Modolell, M. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res., 1997, 57, 1320-1328.
12. Gajate, C.; Santos-Beneit, A.M.; Macho, A.; Lazaro, M.; Hernandez-De Rojas, A.; Modolell, M.; Munoz, E.; Mollinedo, F. Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int. J. Cancer, 2000, 86, 208-218.
13. Jendrossek, V.; Handrick, R. Membrane targeted anticancer drugs: potent inducers of apoptosis and putative radiosensitisers. Curr. Med. Chem. Anti-Canc Agents, 2003, 3, 343-353.
14. Mollinedo, F.; Gajate, C.; Martin-Santamaria, S.; Gago, F. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem., 2004, 11, 3163-3184.
15. Van Blitterswijk, W.J.; Verheij, M. Anticancer mechanisms and clinical application of alkylphospholipids. Biochim. Biophys. Acta, 2013, 1831, 663-674.
16. Mollinedo, F.; Gajate, C.; Modolell, M. The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of FOS and JUN proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells. Biochem. J., 1994, 302, 325-329.
17. Gajate, C.; Santos-Beneit, A.; Modolell, M.; Mollinedo, F. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol. Pharmacol., 1998, 53, 602-612.
18. Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; Van Blitterswijk, W.J.; Verheij, M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res., 1999, 59, 2457-2463.
19. Mollinedo, F.; Gajate, C.; Flores I. Involvement of phospholipase D in the activation of transcription factor AP-1 in human T lymphoid Jurkat cells. J. Immunol., 1994, 153, 2457-2469.
20. Daniel, L.W.; Civoli, F.; Rogers, M.A.; Smitherman, P.K.; Raju, P.A.; Roederer, M. ET-18-OCH3 inhibits nuclear factor-kappa B activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-alpha or interleukin 1 alpha. Cancer Res., 1995, 55, 4844-4849.
21. Gajate, C.; Del Canto-Janez, E.; Acuna, A.U.; Amat-Guerri, F.; Geijo, E.; Santos-Beneit, A.M.; Veldman, R.J.; Mollinedo, F. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J. Exp. Med., 2004, 200, 353-365.
22. Gajate, C.; Mollinedo, F. The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood, 2001, 98, 3860-3863.
23. Mollinedo, F.; Fernandez, M.; Hornillos, V.; Delgado, J.; Amat-Guerri, F.; Acuna, A.U.; Nieto-Miguel, T.; Villa-Pulgarin, J.A.; Gonzalez-Garcia, C.; Cena, V.; Gajate, C. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis., 2011, 2, e158.
24. Nieto-Miguel, T.; Fonteriz, R.I.; Vay, L.; Gajate, C.; Lopez-Hernandez, S.; Mollinedo, F. Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res., 2007, 67, 10368-10378.
25. Cabaner, C.; Gajate, C.; Macho, A.; Munoz, E.; Modolell, M.; Mollinedo, F. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system. Br. J. Pharmacol., 1999, 127, 813-825.
26. Gajate, C.; Fonteriz, R.I.; Cabaner, C.; Alvarez-Noves, G.; Alvarez-Rodriguez, Y.; Modolell, M.; Mollinedo, F. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer, 2000, 85, 674-682.
27. Gajate, C.; Mollinedo, F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood, 2007, 109, 711-719.
28. Mollinedo, F.; De La Iglesia-Vicente, J.; Gajate, C.; De Mendoza, A.; Villa-Pulgarin, J.A.; Campanero, M.A.; Blanco-Prieto, M.J. Lipid raft-targeted therapy in multiple myeloma. Oncogene, 2010, 29, 3748-3757.
29. Mollinedo, F.; De la Iglesia-Vicente, J.; Gajate, C.; De Mendoza, A.; Villa-Pulgarin, J.A.; De Frias, M.; Roue, G.; Gil, J.; Colomer, D.; Campanero, M.A.; Blanco-Prieto, M.J. In vitro and in vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res., 2010, 16, 2046-2054.
30. Busto, J.V.; Sot, J.; Goni, F.M.; Mollinedo, F.; Alonso, A. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine). Biochim. Biophys. Acta, 2007, 1768, 1855-1860.
31. Torrecillas, A.; Aroca-Aguilar, J.D.; Aranda, F.J.; Gajate, C.; Mollinedo, F.; Corbalan-Garcia, S.; De Godos, A.; Gomez-Fernandez, J.C. Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes. Int. J. Pharm., 2006, 318, 28-40.
32. Kosano, H.; Takatani, O. Reduction of epidermal growth factor binding in human breast cancer cell lines by an alkyl-lysophospholipid. Cancer Res., 1988, 48, 6033-6036.
33. Zhou, X.; Lu, X.; Richard, C.; Xiong, W.; Litchfield, D.W.; Bittman, R.; Arthur, G. 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. J. Clin. Invest., 1996, 98, 937-944.
34. Samadder, P.; Richards, C.; Bittman, R.; Bhullar, R.P.; Arthur, G. The antitumor ether lipid 1-O-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1. Anticancer Res., 2003, 23, 2291-2295.
35. Samadder, P.; Arthur, G. Decreased sensitivity to 1-O-octadecyl-2-O-methyl-glycerophosphocholine in MCF-7 cells adapted for serum-free growth correlates with constitutive association of Raf-1 with cellular membranes. Cancer Res., 1999, 59, 4808-4815.
36. Strassheim, D.; Shafer, S.H.; Phelps, S.H.; Williams, C.L. Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res., 2000, 60, 2730-2736.
37. Powis, G.; Seewald, M.J.; Gratas, C.; Melder, D.; Riebow, J.; Modest, E.J. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res., 1992, 52, 2835-2840.
38. Shafer, S.H.; Williams, C.L. Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment. Int. J. Oncol., 2003, 23, 389-400.
39. Kiss, Z.; Crilly, K.S. Alkyl lysophospholipids inhibit phorbol ester-stimulated phospholipase D activity and DNA synthesis in fibroblasts. FEBS Lett., 1997, 412, 313-317.
40. Gratas, C.; Powis, G. Inhibition of phospholipase D by agents that inhibit cell growth. Anticancer Res., 1993, 13, 1239-1244.
41. Zaremberg, V.; McMaster, C.R. Differential partitioning of lipids metabolized by separate yeast glycerol-3-phosphate acyltransferases reveals that phospholipase D generation of phosphatidic acid mediates sensitivity to choline-containing lysolipids and drugs. J. Biol. Chem., 2002, 277, 39035-39044.
42. Rudge, S.A.; Morris, A.J.; Engebrecht, J. Relocalization of phospholipase D activity mediates membrane formation during meiosis. J. Cell Biol., 1998, 140, 81-90.
43. Ruiter, G.A.; Zerp, S.F.; Bartelink, H.; Van Blitterswijk, W.J.; Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs, 2003, 14, 167-173.
44. Kondapaka, S.B.; Singh, S.S.; Dasmahapatra, G.P.; Sausville, E.A.; Roy, K.K. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther., 2003, 2, 1093-1103.
45. Gills, J.J.; Dennis, P.A. Perifosine: update on a novel Akt inhibitor. Curr. Oncol. Rep., 2009, 11, 102-110.
46. Van Blitterswijk, W.J.; Verheij, M. Anticancer alkylphospholipids: Mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des., 2008, 14, 2061-2074.
47. Bellacosa, A.; Chan, T.O.; Ahmed, N.N.; Datta, K.; Malstrom, S.; Stokoe, D.; McCormick, F.; Feng, J.; Tsichlis, P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene, 1998, 17, 313-325.
48. Castillo, S.S.; Brognard, J.; Petukhov, P.A.; Zhang, C.; Tsurutani, J.; Granville, C.A.; Li, M.; Jung, M.; West, K.A.; Gills, J.G.; Kozikowski, A.P.; Dennis, P.A. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res., 2004, 64, 2782-2792.
49. Alam, M.M.; Joh, E.H.; Park, H.; Kim, B.; Kim, D.H.; Lee, Y.S. Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines. Bioorg. Med. Chem., 2013, 21, 2018-2024.
50. Varadhachary, A.S.; Edidin, M.; Hanlon, A.M.; Peter, M.E.; Krammer, P.H.; Salgame, P. Phosphatidylinositol 3'-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J. Immunol., 2001, 166, 6564-6569.
51. Varadhachary, A.S.; Peter, M.E.; Perdow, S.N.; Krammer, P.H.; Salgame, P. Selective up-regulation of phosphatidylinositol 3'-kinase activity in Th2 cells inhibits caspase-8 cleavage at the death-inducing complex: A mechanism for Th2 resistance from Fas-mediated apoptosis. J. Immunol., 1999, 163, 4772-4779.
52. Jones, R.G.; Elford, A.R.; Parsons, M.J.; Wu, L.; Krawczyk, C.M.; Yeh, W.C.; Hakem, R.; Rottapel, R.; Woodgett, J.R.; Ohashi, P.S. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J. Exp. Med., 2002, 196, 335-348.
53. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501.
54. Hanada, M.; Feng, J.; Hemmings, B.A. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim. Biophys. Acta, 2004, 1697, 3-16.
55. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol., 2003, 3, 317-330.
56. Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis, 2004, 9, 667-676.
57. Dillon, R.L.; White, D.E.; Muller, W.J. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene, 2007, 26, 1338-1345.
58. Franke, T.F. PI3K/Akt: Getting it right matters. Oncogene, 2008, 27, 6473-6488.
59. Kawauchi, K.; Ogasawara, T.; Yasuyama, M.; Otsuka, K.; Yamada, O. Regulation and importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. Anticancer Agents Med. Chem., 2009, 9, 1024-1038.
60. Kawauchi, K.; Ogasawara, T.; Yasuyama, M.; Otsuka, K.; Yamada, O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med. Chem., 2009, 9, 550-559.
61. Falasca, M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des., 2010, 16, 1410-1416.
62. Almhanna, K.; Strosberg, J.; Malafa, M. Targeting AKT protein kinase in gastric cancer. Anticancer Res., 2011, 31, 4387-4392.
63. Hers, I.; Vincent, E.E.; Tavare, J.M. Akt signalling in health and disease. Cell Signal., 2011, 23, 1515-1527.
64. Boggs, K.; Rock, C.O.; Jackowski, S. The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. Biochim. Biophys. Acta, 1998, 1389, 1-12.
65. Boggs, K.P.; Rock, C.O.; Jackowski, S. Lysophosphatidylcholine attenuates the cytotoxic effects of the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine. J. Biol. Chem., 1995, 270, 11612-11618.
66. Boggs, K.P.; Rock, C.O.; Jackowski, S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP: Phosphocholine cytidylyltransferase step. J. Biol. Chem., 1995, 270, 7757-7764.
67. Baburina, I.; Jackowski, S. Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP: Phosphocholine cytidylyltransferase. J. Biol. Chem., 1998, 273, 2169-2173.
68. Van der Luit, A.H.; Budde, M.; Ruurs, P.; Verheij, M.; Van Blitterswijk, W.J. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J. Biol. Chem., 2002, 277, 39541-39547.
69. Kennedy, E.P.; Weiss, S.B. The function of cytidine coenzymes in the biosynthesis of phospholipides. J. Biol. Chem., 1956, 222, 193-214.
70. Kent, C. Regulation of phosphatidylcholine biosynthesis. Prog. Lipid Res., 1990, 29, 87-105.
71. Kent, C. Eukaryotic phospholipid biosynthesis. Annu. Rev. Biochem., 1995, 64, 315-343.
72. Kent, C. CTP: Phosphocholine cytidylyltransferase. Biochim. Biophys. Acta, 1997, 1348, 79-90.
73. Esko, J.D.; Raetz, C.R. Autoradiographic detection of animal cell membrane mutants altered in phosphatidylcholine synthesis. Proc. Natl. Acad. Sci. USA, 1980, 77, 5192-5196.
74. Esko, J.D.; Wermuth, M.M.; Raetz, C.R. Thermolabile CDP-choline synthetase in an animal cell mutant defective in lecithin formation. J. Biol. Chem., 1981, 256, 7388-7393.
75. Lykidis, A.; Baburina, I.; Jackowski, S. Distribution of CTP:phosphocholine cytidylyltransferase (CCT) isoforms. Identification of a new CCTbeta splice variant. J. Biol. Chem., 1999, 274, 26992-27001.
76. Northwood, I.C.; Tong, A.H.; Crawford, B.; Drobnies, A.E.; Cornell, R.B. Shuttling of CTP: Phosphocholine cytidylyltransferase between the nucleus and endoplasmic reticulum accompanies the wave of phosphatidylcholine synthesis during the G0 --> G1 transition. J. Biol. Chem., 1999, 274, 26240-26248.
77. Cornell, R.B.; Northwood, I.C. Regulation of CTP:phosphocholine cytidylyltransferase by amphitropism and relocalization. Trends Biochem. Sci., 2000, 25, 441-447.
78. Ridsdale, R.; Tseu, I.; Wang, J.; Post, M. CTP: Phosphocholine cytidylyltransferase alpha is a cytosolic protein in pulmonary epithelial cells and tissues. J. Biol. Chem., 2001, 276, 49148-49155.
79. Besterman, J.M.; Domanico, P.L. Association and metabolism of exogenously-derived lysophosphatidylcholine by cultured mammalian cells: kinetics and mechanisms. Biochemistry, 1992, 31, 2046-2056.
80. Zhou, X.; Arthur, G. Effect of 1-O-octadecyl-2-O-methyl- glycerophosphocholine on phosphatidylcholine and phosphatidylethanolamine synthesis in MCF-7 and A549 cells and its relationship to inhibition of cell proliferation. Eur. J. Biochem., 1995, 232, 881-888.
81. Lu, X.; Arthur, G. The differential susceptibility of A427 and A549 cell lines to the growth-inhibitory effects of ET-18-OCH3 does not correlate with the relative effects of the alkyl-lysophospholipid on the incorporation of fatty acids into cellular phospholipids. Cancer Res., 1992, 52, 2813-2817.
82. Lu, X.; Arthur, G. Perturbations of cellular acylation processes by the synthetic alkyl-lysophospholipid 1-O-octadecyl-2-O-methylglycero-3-phosphocholine do not correlate with inhibition of proliferation of MCF7 and T84 cell lines. Cancer Res., 1992, 52, 2806-2812.
83. Jackowski, S. Cell cycle regulation of membrane phospholipid metabolism. J. Biol. Chem., 1996, 271, 20219-20222.
84. Jackowski, S. Coordination of membrane phospholipid synthesis with the cell cycle. J. Biol. Chem., 1994, 269, 3858-3867.
85. Yang W.; Jackowski S. Lipid activation of CTP: Phosphocholine cytidylyltransferase is regulated by the phosphorylated carboxyl-terminal domain. J. Biol. Chem., 1995, 270, 16503-16506.
86. Pushkareva, M.Y.; Janoff, A.S.; Mayhew, E. Inhibition of cell division but not nuclear division by 1-O-octadecyl-2-O-methyl-Sn-glycero-3-phosphocholine. Cell Biol. Int., 1999, 23, 817-828.
87. Na, H.K.; Chang, C.C.; Trosko, J.E. Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH3, is mediated by inhibition of cytokinesis. Cancer Chemother. Pharmacol., 2003, 51, 209-215.
88. Van der Sanden, M.H.; Houweling, M.; Duijsings, D.; Vaandrager, A.B.; Van Golde, L.M. Inhibition of phosphatidylcholine synthesis is not the primary pathway in hexadecylphosphocholine-induced apoptosis. Biochim. Biophys. Acta, 2004, 1636, 99-107.
89. Wieder, T.; Orfanos, C.E.; Geilen, C.C. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J. Biol. Chem., 1998, 273, 11025-11031.
90. Simons, K.; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol., 2000, 1, 31-39.
91. Barenholz, Y. Cholesterol and other membrane active sterols: from membrane evolution to rafts. Prog. Lipid Res., 2002, 41, 1-5.
92. Simons, K.; Ehehalt, R. Cholesterol, lipid rafts, and disease. J. Clin. Invest., 2002, 110, 597-603.
93. Korade, Z.; Kenworthy, A.K. Lipid rafts, cholesterol, and the brain. Neuropharmacology, 2008, 55, 1265-1273.
94. Munro, S. Lipid rafts: Elusive or illusive? Cell, 2003, 115, 377-388.
95. Megha, Bakht O., London, E. Cholesterol precursors stabilize ordinary and ceramide-rich ordered lipid domains (lipid rafts) to different degrees. Implications for the Bloch hypothesis and sterol biosynthesis disorders. J. Biol. Chem., 2006, 281, 21903-21913.
96. London, E.; Brown, D.A. Insolubility of lipids in triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim. Biophys. Acta, 2000, 1508, 182-195.
97. Maxfield, F.R. Plasma membrane microdomains. Curr. Opin. Cell Biol., 2002, 14, 483-487.
98. Simons, K.; Gerl, M.J. Revitalizing membrane rafts: New tools and insights. Nat. Rev. Mol. Cell Biol., 2010, 11, 688-699.
99. Hanzal-Bayer, M.F.; Hancock, J.F. Lipid rafts and membrane traffic. FEBS Lett., 2007, 581, 2098-2104.
100. Suzuki, K.G. Lipid rafts generate digital-like signal transduction in cell plasma membranes. Biotechnol. J., 2012, 7, 753-761.
101. Busto, J.V.; Del Canto-Jañez, E.; Goñi, F.M.; Mollinedo, F.; Alonso, A. Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug. J. Chem. Biol., 2008, 1, 89-94.
102. Ausili, A.; Torrecillas, A.; Aranda, F.J.; Mollinedo, F.; Gajate, C.; Corbalan-Garcia, S.; De Godos, A.; Gomez-Fernandez, J.C. Edelfosine is incorporated into rafts and alters their organization. J. Phys. Chem. B, 2008, 112, 11643-11654.
103. Miyaji, M.; Jin, Z.X.; Yamaoka, S.; Amakawa, R.; Fukuhara, S.; Sato, S.B.; Kobayashi, T.; Domae, N.; Mimori, T.; Bloom, E.T.; Okazaki, T.; Umehara, H. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J. Exp. Med., 2005, 202, 249-259.
104. Chakrabandhu, K.; Herincs, Z.; Huault, S.; Dost, B.; Peng, L.; Conchonaud, F.; Marguet, D.; He, H.T.; Hueber, A.O. Palmitoylation is required for efficient Fas cell death signaling. Embo J., 2007, 26, 209-220.
105. Lee, K.H.; Feig, C.; Tchikov, V.; Schickel, R.; Hallas, C.; Schutze, S.; Peter, M.E.; Chan, A.C. The role of receptor internalization in CD95 signaling. Embo J, 2006, 25, 1009-1023.
106. Delmas, D.; Rebe, C.; Lacour, S.; Filomenko, R.; Athias, A.; Gambert, P.; Cherkaoui-Malki, M.; Jannin, B.; Dubrez-Daloz, L.; Latruffe, N.; Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem., 2003, 278, 41482-41490.
107. Delmas, D.; Rebe, C.; Micheau, O.; Athias, A.; Gambert, P.; Grazide, S.; Laurent, G.; Latruffe, N.; Solary, E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 2004, 23, 8979-8986.
108. Reis-Sobreiro, M.; Gajate, C.; Mollinedo, F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene, 2009, 28, 3221-3234.
109. Lacour, S.; Hammann, A.; Grazide, S.; Lagadic-Gossmann, D.; Athias, A.; Sergent, O.; Laurent, G.; Gambert, P.; Solary, E.; Dimanche-Boitrel, M.T. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res, 2004, 64, 3593-3598.
110. Gajate, C.; Mollinedo, F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J. Biol. Chem., 2005, 280, 11641-11647.
111. Xu, Z.X.; Ding, T.; Haridas, V.; Connolly, F.; Gutterman, J.U. Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts. PLoS One, 2009, 4, e8532.
112. Stel, A.J.; Cate, T.B.; Jacobs, S.; Kok, J.W.; Spierings, D.C.; Dondorff, M.; Helfrich, W.; Kluin-Nelemans, H.C.; De Leij, L.F.; Withoff, S.; Kroesen, B.J. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to Fas-induced apoptosis. J. Immunol., 2007, 178, 2287-2295.
113. DeMorrow, S.; Glaser, S.; Francis, H.; Venter, J.; Vaculin, B.; Vaculin, S.; Alpini, G. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of Fas and Fas ligand to lipid rafts. J. Biol. Chem., 2007, 282, 13098-13113.
114. Rao-Bindal, K.; Zhou, Z.; Kleinerman, E.S. MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis., 2012, 3, e369.
115. Kischkel, F.C.; Hellbardt, S.; Behrmann, I.; Germer, M.; Pawlita, M.; Krammer, P.H.; Peter, M.E. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J., 1995, 14, 5579-5588.
116. Wang, L.; Yang, J.K.; Kabaleeswaran, V.; Rice, A.J.; Cruz, A.C.; Park, A.Y.; Yin, Q.; Damko, E.; Jang, S.B.; Raunser, S.; Robinson, C.V.; Siegel, R.M.; Walz, T.; Wu, H. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat. Struct. Mol. Biol., 2010, 17, 1324-1329.
117. Esposito, D.; Sankar, A.; Morgner, N.; Robinson, C.V.; Rittinger, K.; Driscoll, P.C. Solution NMR investigation of the CD95/FADD homotypic death domain complex suggests lack of engagement of the CD95 C terminus. Structure, 2010, 18, 1378-1390.
118. Hymowitz, S.G.; Dixit, V.M. Unleashing cell death: The Fas-FADD complex. Nat. Struct. Mol. Biol., 2010, 17, 1289-1290.
119. Ashkenazi, A.; Dixit, V.M. Death receptors: Signaling and modulation. Science, 1998, 281, 1305-1308.
120. Salvesen, G.S.; Dixit, V.M. Caspase activation: the induced-proximity model. Proc. Natl. Acad. Sci. USA, 1999, 96, 10964-10967.
121. Li, H.; Zhu, H.; Xu, C.J.; Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 1998, 94, 491-501.
122. Luo, X.; Budihardjo, I.; Zou, H.; Slaughter, C.; Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 1998, 94, 481-490.
123. Mollinedo, F.; Gajate, C. Fas/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy. Drug Resist., Updat, 2006, 9, 51-73.
124. Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One, 2009, 4, e5044.
125. Nieto-Miguel, T.; Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. Oncogene, 2008, 27, 1779-1787.
126. Gajate, C.; Gonzalez-Camacho, F.; Mollinedo, F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun., 2009, 380, 780-784.
127. Chen, Y.R.; Wang, X.; Templeton, D.; Davis, R.J.; Tan, T.H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem., 1996, 271, 31929-31936.
128. Gajate, C.; An, F.; Mollinedo, F. Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95-and mitochondrial-mediated mechanism. Clin. Cancer Res., 2003, 9, 1535-1545.
129. Gajate, C.; Matos-da-Silva, M.; Dakir, E.L.; Fonteriz, R.I.; Alvarez, J.; Mollinedo, F. Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. Oncogene, 2012, 31, 2627-2639.
130. Hueber, A.O.; Bernard, A.M.; Herincs, Z.; Couzinet, A.; He, H.T. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep., 2002, 3, 190-196.
131. Scheel-Toellner, D.; Wang, K.; Singh, R.; Majeed, S.; Raza, K.; Curnow, S.J.; Salmon, M.; Lord, J.M. The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem. Biophys. Res. Commun., 2002, 297, 876-879.
132. Friesen, C.; Herr, I.; Krammer, P.H.; Debatin, K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 1996, 2, 574-577.
133. Muller, M.; Strand, S.; Hug, H.; Heinemann, E.M.; Walczak, H.; Hofmann, W.J.; Stremmel, W.; Krammer, P.H.; Galle, P.R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 1997, 99, 403-413.
134. Friesen, C.; Fulda, S.; Debatin, K.M. Cytotoxic drugs and the CD95 pathway. Leukemia, 1999, 13, 1854-1858.
135. Mollinedo, F.; Gajate, C. FasL-independent activation of Fas. In: Wajant H, editor. Fas Signaling. Georgetown, TX: Landes Bioscience and Springer Science, 2006. p. Chapter 2, pp. 13-27.
136. Watanabe, S.; Mukaida, N.; Ikeda, N.; Akiyama, M.; Harada, A.; Nakanishi, I.; Nariuchi, H.; Watanabe, Y.; Matsushima, K. Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF. Int. Immunol., 1995, 7, 1037-1046.
137. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature, 1993, 364, 806-809.
138. Jo, M.; Kim, T.H.; Seol, D.W.; Esplen, J.E.; Dorko, K.; Billiar, T.R.; Strom, S.C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med., 2000, 6, 564-567.
139. Beneteau, M.; Pizon, M.; Chaigne-Delalande, B.; Daburon, S.; Moreau, P.; De Giorgi, F.; Ichas, F.; Rebillard, A.; Dimanche-Boitrel, M.T.; Taupin, J.L.; Moreau, J.F.; Legembre, P. Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway. Mol. Cancer Res., 2008, 6, 604-613.
140. Freeburn, R.W.; Wright, K.L.; Burgess, S.J.; Astoul, E.; Cantrell, D.A.; Ward, S.G. Evidence that SHIP-1 contributes to phosphatidylinositol 3,4,5-trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors. J. Immunol., 2002, 169, 5441-5450.
141. Gazitt, Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia, 1999, 13, 1817-1824.
142. Gazitt, Y.; Shaughnessy P.; Montgomery W. Apoptosis-induced by TRAIL and TNF-alpha in human multiple myeloma cells is not blocked by BCL-2. Cytokine, 1999, 11, 1010-1019.
143. Mitsiades, C.S.; Treon, S.P.; Mitsiades, N.; Shima, Y.; Richardson, P.; Schlossman, R.; Hideshima, T.; Anderson, K.C. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood, 2001, 98, 795-804.
144. De Mendoza, A.E.; Campanero, M.A.; De la Iglesia-Vicente, J.; Gajate, C.; Mollinedo, F.; Blanco-Prieto, M.J. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin. Cancer Res., 2009, 15, 858-864.
145. Zerp, S.F.; Vink, S.R.; Ruiter, G.A.; Koolwijk, P.; Peters, E.; Van Der Luit, A.H.; De Jong, D.; Budde, M.; Bartelink, H.; Van Blitterswijk, W.J.; Verheij, M. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. Anticancer Drugs, 2008, 19, 65-75.
146. Mollinedo, F.; Gajate, C.; Morales, AI.; Del Canto-Janez, E.; Justies, N.; Collia, F.; Rivas, J.V.; Modolell, M.; Iglesias, A. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J. Pharmacol. Exp. Ther., 2009, 329, 439-449.
147. Beneteau, M.; Daburon, S.; Moreau, J.F.; Taupin, J.L.; Legembre, P. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP. Cancer Res., 2007, 67, 108-115.
148. Van Blitterswijk, W.J.; Klarenbeek, J.B.; Van der Luit, A.H.; Alderliesten, M.C.; Van Lummel, M.; Verheij, M. Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency. Biochem. J., 2009, 425, 225-234.
149. Scaffidi, C.; Schmitz, I.; Krammer, P.H.; Peter, M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem., 1999, 274, 1541-1548.
150. Scaffidi, C.; Fulda, S.; Srinivasan, A.; Friesen, C.; Li, F.; Tomaselli, K.J.; Debatin, K.M.; Krammer, P.H.; Peter, M.E. Two CD95 (APO-1/Fas) signaling pathways. Embo J., 1998, 17, 1675-1687.
151. Scaffidi, C.; Schmitz, I.; Zha, J.; Korsmeyer, S.J.; Krammer, P.H.; Peter, M.E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 1999, 274, 22532-22538.
152. Eramo, A.; Sargiacomo, M.; Ricci-Vitiani, L.; Todaro, M.; Stassi, G.; Messina, C.G.; Parolini, I.; Lotti, F.; Sette, G.; Peschle, C.; De Maria, R. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol., 2004, 34, 1930-1940.
153. Legembre, P.; Daburon, S.; Moreau, P.; Ichas, F.; De Giorgi, F.; Moreau, J.F.; Taupin, J.L. Amplification of Fas-mediated apoptosis in type II cells via microdomain recruitment. Mol. Cell Biol., 2005, 25, 6811-6820.
154. Van Der Luit, A.H.; Budde, M.; Verheij, M.; Van Blitterswijk, W.J. Different modes of internalization of apoptotic alkyl-lysophospholipid and cell-rescuing lysophosphatidylcholine. Biochem. J., 2003, 374, 747-753.
155. Zaremberg, V.; Gajate, C.; Cacharro, L.M.; Mollinedo, F.; McMaster, C.R. Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. J. Biol. Chem., 2005, 280, 38047-38058.
156. Van der Luit, A.H.; Vink, S.R.; Klarenbeek, J.B.; Perrissoud, D.; Solary, E.; Verheij, M.; Van Blitterswijk, W.J. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells. Mol. Cancer Ther., 2007, 6, 2337-2345.
157. Israelachvili, J.N.; Marcelja, S.; Horn, R.G. Physical principles of membrane organization. Q Rev. Biophys., 1980, 13, 121-200.
158. Heczkova, B.; Slotte, J.P. Effect of anti-tumor ether lipids on ordered domains in model membranes. FEBS Lett., 2006, 580, 2471-2476.
159. Hac-Wydro, K.; Dynarowicz-Latka, P.; Wydro, P.; Bak, K. Edelfosine disturbs the sphingomyelin-cholesterol model membrane system in a cholesterol-dependent way - the Langmuir monolayer study. Colloids Surf. B Biointerf., 2011, 88, 635-640.
160. Hac-Wydro, K.; Dynarowicz-Latka, P. Searching for the role of membrane sphingolipids in selectivity of antitumor ether lipid-edelfosine. Colloids Surf. B Biointerf., 2010, 81, 492-497.
161. Hac-Wydro, K.; Dynarowicz-Latka, P. The relationship between the concentration of ganglioside GM1 and antitumor activity of edelfosine--the Langmuir monolayer study. Colloids Surf. B Biointerfaces, 2010, 81, 385-388.
162. Harder, T.; Scheiffele, P.; Verkade, P.; Simons, K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol., 1998, 141, 929-942.
163. Radhakrishnan, A.; Anderson, T.G.; McConnell, H.M. Condensed complexes, rafts, and the chemical activity of cholesterol in membranes. Proc. Natl. Acad. Sci USA, 2000, 97, 12422-12427.
164. Alonso, M.A.; Millan, J. The role of lipid rafts in signalling and membrane trafficking in T lymphocytes. J. Cell Sci., 2001, 114, 3957-3965.
165. Millan, J.; Qaidi, M.; Alonso, M.A. Segregation of co-stimulatory components into specific T cell surface lipid rafts. Eur. J. Immunol., 2001, 31, 467-473.
166. Molander-Melin, M.; Blennow, K.; Bogdanovic, N.; Dellheden, B.; Mansson, J.E.; Fredman, P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development.; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem., 2005, 92, 171-182.
167. Cazet, A.; Groux-Degroote, S.; Teylaert, B.; Kwon, K.M.; Lehoux, S.; Slomianny, C.; Kim, C.H.; Le Bourhis, X.; Delannoy, P. GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. Biol. Chem., 2009, 390, 601-609.
168. Hakomori, S. Role of gangliosides in tumor progression. Prog. Brain Res., 1994, 101, 241-250.
169. Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res., 1996, 56, 5309-5318.
170. Hatano, K.; Miyamoto, Y.; Nonomura, N.; Kaneda, Y. Expression of gangliosides, GD1a and sialyl paragloboside, is regulated by NF-kappaB-dependent transcriptional control of alpha2,3-sialyltransferase I, II and VI in human castration-resistant prostate cancer cells. Int. J. Cancer, 2010, In Press,
171. Mollinedo, F.; Gajate, C. Lipid rafts, death receptors and CASMERs: new insights for cancer therapy. Future Oncol., 2010, 6, 491-494.
172. Mollinedo, F.; Gajate, C. Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol., 2010, 6, 811-821.
173. Legembre, P.; Mollinedo, F. The plasma membrane: A catalyst in the decision to die or not to die? Rec. Pat Anticancer Drug Discov., 2011, 6, 271-273.
174. Gajate, C.; Mollinedo, F. Lipid rafts and Fas/CD95 signaling in cancer chemotherapy. Rec. Pat. Anticancer Drug Discov., 2011, 6, 274-283.
175. Reis-Sobreiro, M.; Roue, G.; Moros, A.; Gajate, C.; De la Iglesia-Vicente, J.; Colomer, D.; Mollinedo, F. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J., 2013, 3, e118.
176. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer, 2005, 5, 761-772.
177. Remacle-Bonnet, M.; Garrouste, F.; Baillat, G.; Andre, F.; Marvaldi, J.; Pommier, G. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am. J. Pathol., 2005, 167, 761-773.
178. Cuesta-Marban, A.; Botet, J.; Czyz, O.; Cacharro, L.M.; Gajate, C.; Hornillos, V.; Delgado, J.; Zhang, H.; Amat-Guerri, F.; Acuna, A.U.; McMaster, C.R.; Revuelta, J.L.; Zaremberg, V.; Mollinedo, F. Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast. J. Biol. Chem., 2013, 288, 8405-8418.
179. Czyz, O.; Bitew, T.; Cuesta-Marban, A.; McMaster, C.R.; Mollinedo, F.; Zaremberg, V. Alteration of plasma membrane organization by an anticancer lysophosphatidylcholine analogue induces intracellular acidification and internalization of plasma membrane transporters in yeast. J. Biol. Chem., 2013, 288, 8419-8432.
180. Mollinedo, F. Lipid raft involvement in yeast cell growth and death. Front. Oncol., 2012, 2, 140.
181. Besson, P.; Gore, J.; Vincent, E.; Hoinard, C.; Bougnoux, P. Inhibition of Na+/H+ exchanger activity by an alkyl-lysophospholipid analogue in a human breast cancer cell line. Biochem Pharmacol, 1996, 51, 1153-1158.
182. Nieto-Miguel, T.; Gajate, C.; Mollinedo, F. Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J. Biol. Chem., 2006, 281, 14833-14840.
183. Ron, D.; Habener, J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev., 1992, 6, 439-453.
184. Urano F.; Wang X.; Bertolotti A.; Zhang Y.; Chung P.; Harding HP.; Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science, 2000, 287, 664-666.
185. Hitomi J.; Katayama T.; Eguchi Y.; Kudo T.; Taniguchi M.; Koyama Y.; Manabe T.; Yamagishi S.; Bando Y.; Imaizumi K.; Tsujimoto Y.; Tohyama M. Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and a beta-induced cell death. J Cell Biol, 2004, 165, 347-356.
186. Ng FW.; Nguyen M.; Kwan T.; Branton PE.; Nicholson DW.; Cromlish JA.; Shore GC. P28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum. J Cell Biol, 1997, 139, 327-338.
187. Breckenridge DG.; Germain M.; Mathai JP.; Nguyen M.; Shore GC. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene, 2003, 22, 8608-8618.
188. Breckenridge DG.; Stojanovic M.; Marcellus RC.; Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol, 2003, 160, 1115-1127.
189. Quesada E.; Delgado J.; Gajate C.; Mollinedo F.; Acuna AU.; Amat-Guerri F. Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells. J Med Chem, 2004, 47, 5333-5335.
190. Kuerschner L.; Richter D.; Hannibal-Bach HK.; Gaebler A.; Shevchenko A.; Ejsing CS.; Thiele C. Exogenous ether lipids predominantly target mitochondria. PLoS One, 2012, 7, e31342.
191. Nagan N.; Zoeller RA. Plasmalogens: biosynthesis and functions. Prog Lipid Res, 2001, 40, 199-229.
192. Burgeiro A.; Pereira CV.; Carvalho FS.; Pereira GC.; Mollinedo F.; Oliveira PJ. Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition. Mitochondrion, 2013, 13, 25-35.
193. Ciarlo L.; Manganelli V.; Garofalo T.; Matarrese P.; Tinari A.; Misasi R.; Malorni W.; Sorice M. Association of fission proteins with mitochondrial raft-like domains. Cell Death Differ, 2010, 17, 1047-1058.
194. Sorice M.; Manganelli V.; Matarrese P.; Tinari A.; Misasi R.; Malorni W.; Garofalo T. Cardiolipin-enriched raft-like microdomains are essential activating platforms for apoptotic signals on mitochondria. FEBS Lett., 2009, 583, 2447-2450.
195. Zheng, Y.Z.; Berg, K.B.; Foster, L.J. Mitochondria do not contain lipid rafts, and lipid rafts do not contain mitochondrial proteins. J. Lipid Res., 2009, 50, 988-998.
196. Garofalo, T.; Giammarioli, A.M.; Misasi, R.; Tinari, A.; Manganelli, V.; Gambardella, L.; Pavan, A.; Malorni, W.; Sorice, M. Lipid microdomains contribute to apoptosis-associated modifications of mitochondria in T cells. Cell Death Differ., 2005, 12, 1378-1389.
197. Grimm, S.; Brdiczka, D. The permeability transition pore in cell death. Apoptosis, 2007, 12, 841-855.
198. Soccio, R.E.; Breslow, J.L. Intracellular cholesterol transport. Arterioscler. Thromb. Vasc. Biol, 2004, 24, 1150-1160.
199. De Pinto, V.; Benz, R.; Palmieri, F. Interaction of non-classical detergents with the mitochondrial porin. A new purification procedure and characterization of the pore-forming unit. Eur. J. Biochem., 1989, 183, 179-187.
200. Ziolkowski, W.; Szkatula, M.; Nurczyk, A.; Wakabayashi, T.; Kaczor, J.J.; Olek, R.A.; Knap, N.; Antosiewicz, J.; Wieckowski, M.R.; Wozniak, M. Methyl-beta-cyclodextrin induces mitochondrial cholesterol depletion and alters the mitochondrial structure and bioenergetics. FEBS Lett., 2010, 584, 4606-4610.
201. Sprong, H.; Van der Sluijs, P.; Van Meer, G. How proteins move lipids and lipids move proteins. Nat. Rev. Mol. Cell Biol., 2001, 2, 504-513.
202. Goonesinghe, A.; Mundy, E.S.; Smith, M.; Khosravi-Far, R.; Martinou, J.C.; Esposti, M.D. Pro-apoptotic Bid induces membrane perturbation by inserting selected lysolipids into the bilayer. Biochem. J., 2005, 387, 109-118.
203. Cereghetti, G.M.; Scorrano, L. The many shapes of mitochondrial death. Oncogene, 2006, 25, 4717-4724.
204. De Brito, O.M.; Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature, 2008, 456, 605-610.
205. Voelker, D.R. Characterization of phosphatidylserine synthesis and translocation in permeabilized animal cells. J. Biol. Chem., 1990, 265, 14340-14346.
206. Voelker, D.R. Lipid transport pathways in mammalian cells. Experientia, 1990, 46, 569-579.
207. Vance, J.E. Phospholipid synthesis in a membrane fraction associated with mitochondria. J. Biol. Chem., 1990, 265, 7248-7256.
208. Ardail, D.; Gasnier, F.; Lerme, F.; Simonot, C.; Louisot, P.; Gateau-Roesch, O. Involvement of mitochondrial contact sites in the subcellular compartmentalization of phospholipid biosynthetic enzymes. J. Biol. Chem., 1993, 268, 25985-25992.
209. Gasnier, F.; Ardail, D.; Febvay, G.; Simonot, C.; Lerme, F.; Guillaud, J.; Louisot, P.; Gateau-Roesch, O. Further evidence for both functional and structural microcompartmentation within the membranes of two associated organelles, mitochondrion and endoplasmic reticulum. Biochem. Biophys. Res. Commun., 1993, 195, 1365-1370.
210. Gaigg, B.; Simbeni, R.; Hrastnik, C.; Paltauf, F.; Daum, G. Characterization of a microsomal subfraction associated with mitochondria of the yeast, Saccharomyces cerevisiae. Involvement in synthesis and import of phospholipids into mitochondria. Biochim. Biophys. Acta, 1995, 1234, 214-220.
211. Shiao, Y.J.; Lupo, G.; Vance, J.E. Evidence that phosphatidylserine is imported into mitochondria via a mitochondria-associated membrane and that the majority of mitochondrial phosphatidylethanolamine is derived from decarboxylation of phosphatidylserine. J. Biol. Chem., 1995, 270, 11190-11198.
212. Kornmann, B.; Currie, E.; Collins, S.R.; Schuldiner, M.; Nunnari, J.; Weissman, J.S.; Walter, P. An ER-mitochondria tethering complex revealed by a synthetic biology screen. Science, 2009, 325, 477-481.
213. Kornmann, B.; Walter, P. ERMES-mediated ER-mitochondria contacts: molecular hubs for the regulation of mitochondrial biology. J. Cell Sci, 2010, 123, 1389-1393.
214. Osman, C.; Voelker, D.R.; Langer, T. Making heads or tails of phospholipids in mitochondria. J. Cell Biol., 2011, 192, 7-16.
215. Chiarini, F.; Del Sole, M.; Mongiorgi, S.; Gaboardi G; Cappellini, A.; Mantovani, I.; Follo, M.Y.; McCubrey, J.A.; Martelli, A.M. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia, 2008, 22, 1106-1116.
216. Vink, S.R.; Van der Luit, A.H.; Klarenbeek, J.B.; Verheij, M.; Van Blitterswijk, W.J. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells. Biochem. Pharmacol., 2007, 74, 1456-1465.